All In MedTech

Device Trial Radar · NCT03811171

Break Wave(TM) Extracorporeal Lithotripter First-in-Human Study

A Study of the SonoMotion Break Wave(TM) System for the Comminution of Urinary Tract Stones

Last checked: Nov 20, 2026Latest source record: Jul 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Aug 20, 2019

Primary completion

Jan 30, 2027

Study completion Mar 30, 2027

Sponsor

Lead sponsor
SonoMotionNot on our public-company list
Sponsor type
Industry
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted
Jan 22, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label, multi-center, single-arm (non-randomized) study to assess the safety and effectiveness of breaking stones in the upper urinary tract using the SonoMotion Break Wave technology. Up to 30 subjects will be included. The procedure will be performed in a hospital surgical environment as an outpatient (without being admitted) or in a non-surgical environment such as a clinic or office procedure room. The procedure will be performed under varying levels of anesthesia ranging from no anesthesia to general anesthesia (fully asleep). Stones will be limited to ≤ 10 mm for lower pole stones and ≤ 20 mm everywhere else. Safety will be measured by the self-reported occurrences of adverse events, unplanned emergency department or clinic visits, and the need for further intervention. Fragmentation will be measured by self-reported stone passage and a comparison of computed tomography (CT) images before and after the procedure.

Conditions

  • Renal Calculi
  • Urinary Calculi

Interventions

  • Break Wave extracorporeal lithotripsyDevice

    The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an 85 mm aperture diameter therapy probe driven by a high voltage generator. The therapy probe has a cavity in the middle to accommodate coaxial alignment of an ultrasound imaging probe for treatment guidance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Effectiveness Outcome - Stone FragmentationTime frame: 12 weeks post-treatment
  2. Primary Safety Outcome - Hematoma, urinary tract sepsis, or cardiac arrythmiaTime frame: 12 weeks post-treatment

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California San Diego Health

    San Diego, California · Completed

  • University of California, San Francisco

    San Francisco, California · Completed

  • University of Washington Medical Center

    Seattle, Washington · Completed

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.